Related Experiment Video
Updated: Jan 8, 2026

Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study
Claire Dossier1, Jean-Daniel Delbet2, Olivia Boyer3
1Department of Pediatric Nephrology, Hôpital Armand-Trousseau, APHP, Paris, France. claire.dossier@aphp.fr.
Insights
Idiopathic nephrotic syndrome (INS) in children often relapses, with 79% experiencing a first relapse. Early intervention is crucial to minimize long-term steroid and immunosuppression use in frequent relapsers.
Area of Science:
- Pediatric Nephrology
- Clinical Pediatrics
- Immunology
Background:
- Idiopathic nephrotic syndrome (INS) treatment in children lacks standardized optimal regimens.
- Understanding INS disease course is vital for personalized treatment strategies.
Purpose of the Study:
- To evaluate the 5-year outcomes of children with INS treated with the French steroid protocol.
- To identify factors influencing relapse rates and long-term treatment needs in pediatric INS.
Main Methods:
- Prospective, multicentric, multiethnic NEPHROVIR study.
- Inclusion of 188 children with INS from December 2007 to May 2010.
- Treatment followed the French steroid protocol; 5-year follow-up data collected.
Main Results:
- 93% of patients (174/188) were steroid-sensitive; 6% required IV steroid pulses.
- Relapse-free rate was 21%; 79% (138/174) experienced a first relapse within 8.3 months.
- Age under 4 years at onset was the sole predictor of relapse; 83% of frequent relapsers remained on long-term medication.
Conclusions:
- Current treatment for initial INS flares requires improvement to reduce relapse prevalence.
- Minimizing relapses is key to decreasing prolonged exposure to steroids and immunosuppressants.
- Further research needed for optimized pediatric INS management and reduced long-term drug dependency.
Background:
The optimal therapeutic regimen for children at onset of idiopathic nephrotic syndrome (INS) is still under debate. A better knowledge of the disease's course is necessary to design more appropriate and/or personalized treatment protocols.
Methods:
We report the 5-year outcome of patients included from December 2007 to May 2010 in the prospective multicentric and multiethnic population-based NEPHROVIR study. Patients were treated at onset according to the French steroid protocol (3990 mg/m2, 18 weeks). Data were collected at 5 years or last follow-up.
Results:
Out of the 188 children with nephrotic syndrome (121 boys, 67 girls; median age 4.1 years), 174 (93%) were steroid-sensitive. Six percent of steroid-sensitive patients required intravenous steroid pulses to get into remission. Relapse-free rate for steroid-sensitive patients was 21% (36/174) at last follow-up (median 72 months). A first relapse occurred in138 steroid sensitive patients (79%) with a median time of 8.3 months (IQ 3.4-11.3). Out of the 138 relapsers, 43 were frequent relapsers. Age at onset below 4 years was the only predictive factor of relapse, while gender, ethnicity, and delay to first remission were not. At 96 months of follow-up, 83% of frequent relapsers were still under steroids and/or immunosuppressive drugs.
Conclusions:
The treatment of the first flare deserves major improvements in order to reduce the prevalence of relapsers and the subsequent long-lasting exposure to steroids and immunosuppression.
More Related Videos
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury III: Clinical Manifestations
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction